Capricor Therapeutics reported $-5939000 in EBITDA for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ebitda Change
Bioline Rx BLRX:US $ -5.91M 0.52M
Capricor Therapeutics CAPR:US $ -5.94M 2.84M
Cytokinetics CYTK:US $ -76.52M 58.35M
Cytori Therapeutics CYTX:US $ -3.78M 0.27M
Geron GERN:US $ -28.62M 2.3M
Newlink Genetics NLNK:US $ -7.72M 1.16M
Prothena PRTA:US -37744000 4.89M
Ptc Therapeutics PTCT:US $ -60.21M 5.71M
Sarepta Therapeutics SRPT:US $ -76.16M 19.51M
Vascular Biogenics VBLT:US -10226000 1.45M
Vital Therapies VTL:US $ -21.41M 0.26M